Solid Biosciences Inc.
SLDB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001707502
No open-market purchases or sales by Solid Biosciences Inc. insiders were filed in the last 90 days; 157 institutions reported holding it in 13F filings for Q2 2026, worth $1.14B in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in Solid Biosciences Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 37
- +1 vs. Q2 2023
- Shares held
- 16.2M
- −170.4K (−1.0%) vs. Q2 2023
- Total value
- $40.7M
- −$44.9M (−52.4%) vs. Q2 2023
- New holders
- 3
- 7 more added
- Sold out
- 2
- 9 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SLDB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 157 | $1.14B |
| Q1 2026 | 150 | $717.4M |
| Q4 2025 | 132 | $459.2M |
| Q3 2025 | 129 | $505.2M |
| Q2 2025 | 116 | $403.4M |
| Q1 2025 | 125 | $293.2M |
| Q4 2024 | 90 | $145.3M |
| Q3 2024 | 92 | $249.8M |
| Q2 2024 | 80 | $213.2M |
| Q1 2024 | 56 | $465.9M |
| Q4 2023 | 40 | $102.2M |
| Q3 2023 | 37 | $40.7M |
| Q2 2023 | 36 | $85.6M |
| Q1 2023 | 39 | $74.8M |
| Q4 2022 | 35 | $85.6M |
| Q3 2022 | 58 | $33.4M |
| Q2 2022 | 67 | $39.5M |
| Q1 2022 | 78 | $83.3M |
| Q4 2021 | 82 | $132.2M |
| Q3 2021 | 91 | $184.3M |
| Q2 2021 | 92 | $293.4M |
| Q1 2021 | 104 | $437.6M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Solid Biosciences Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Simplex Trading, LLC | 27 | $0 | 0.00% | +27 | New |
| Rhumbline Advisers | 0 | $2 | 0.00% | −27−100.0% | Reduced |
| Qube Research & Technologies Ltd | 1 | $3 | 0.00% | +1 | New |
| Parallel Advisors, LLC | 6 | $15 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 15 | $38 | 0.00% | −178−92.2% | Reduced |
| Advisor Group Holdings, Inc. | 30 | $75 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 69 | $174 | 0.00% | −56−44.8% | Reduced |
| JPMorgan Chase & Co | 133 | $335 | 0.00% | 00.0% | Unchanged |
| First Manhattan Co | 133 | $335 | 0.00% | 00.0% | Unchanged |
| Group One Trading, L.P. | 214 | $539 | 0.00% | 00.0% | Unchanged |
| FMR LLC | 300 | $756 | 0.00% | +299+29,900.0% | Added |
| Manchester Capital Management LLC | 1,000 | $2.52K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 1,488 | $3.75K | 0.00% | +1,488 | New |
| Lazard Asset Management LLC | 2,332 | $5.00K | 0.00% | +116+5.2% | Added |
| Bank of America Corp | 2,326 | $5.86K | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 2,548 | $6.00K | 0.00% | +1,413+124.5% | Added |
| Barclays PLC | 4,417 | $11.1K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 4,598 | $11.6K | 0.00% | −20−0.4% | Reduced |
| Northern Trust Corp | 11,434 | $28.8K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 13,394 | $33.8K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 28,570 | $72.0K | 0.00% | +900+3.3% | Added |
| Bridgeway Capital Management, LLC | 36,057 | $90.9K | 0.00% | +10,000+38.4% | Added |
| Dimensional Fund Advisors LP | 55,090 | $138.8K | 0.00% | −7,074−11.4% | Reduced |
| Caas Capital Management LP | 64,112 | $161.6K | 0.04% | −37,569−36.9% | Reduced |
| Walleye Capital LLC | 91,109 | $229.6K | 0.00% | −1,994−2.1% | Reduced |
| Geode Capital Management, LLC | 102,513 | $258.4K | 0.00% | +13,254+14.8% | Added |
| BlackRock Inc. | 131,283 | $330.8K | 0.00% | −6,761−4.9% | Reduced |
| Vanguard Group Inc | 250,060 | $630.2K | 0.00% | +2,018+0.8% | Added |
| Great Point Partners LLC | 450,403 | $1.14M | 0.21% | −134,055−22.9% | Reduced |
| Alyeska Investment Group, L.P. | 646,604 | $1.63M | 0.01% | 00.0% | Unchanged |
| Artal Group S.A. | 909,219 | $2.29M | 0.10% | 00.0% | Unchanged |
| Laurion Capital Management LP | 928,169 | $2.34M | 0.06% | 00.0% | Unchanged |
| Finepoint Capital LP | 961,251 | $2.42M | 1.21% | 00.0% | Unchanged |
| Camber Capital Management LP | 1,418,439 | $3.57M | 0.13% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 3,130,422 | $7.89M | 0.88% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 3,426,286 | $8.63M | 0.17% | 00.0% | Unchanged |
| Perceptive Advisors LLC | 3,495,933 | $8.81M | 0.30% | 00.0% | Unchanged |
| CIBC Asset Management Inc | 0 | $0 | 0.00% | −12,083−100.0% | Sold out |
| Baker Avenue Asset Management, LP | 0 | $0 | 0.00% | −66−100.0% | Sold out |